

Original Article

Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients

Jing Gao, Ting-ting Wang, Jing-wei Yu, Yan-yan Li, Lin Shen*

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China

DOI: 10.1007/s11670-011-0271-4

©Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2011

ABSTRACT

Objective: To analyze the relationship between KRAS, BRAF mutations and the response to Cetuximab in Chinese colorectal cancer patients.

Methods: A total of 273 Chinese colorectal cancer patients were evaluated for KRAS and BRAF mutations by Sanger sequencing. Among them, 59 patients with metastatic colorectal cancer (mCRC) were treated with Cetuximab in combination with chemotherapy from August 2005 to July 2009. Statistical analysis was conducted to assess the relationship between KRAS, BRAF mutations and the response or survival of 59 mCRC patients.

Results: KRAS and BRAF mutation rates were 38.5% (105/273) and 5.1% (14/273), respectively, and KRAS/BRAF mutations were mutually exclusive. Among 59 patients treated with Cetuximab plus chemotherapy, KRAS and BRAF mutations were identified in 11 and 5 patients, respectively. The response rates and median progression-free survivals (PFS) in KRAS wild-type and mutant patients were 35.4% (17/48) vs. 9.1% (1/11) ($P=0.054$) and 153 days vs. 99 days ($P=0.01$), respectively. Also, the response rates and median PFS in BRAF wild-type and mutant patients were 37.2% (16/43) vs. 20% (1/5) ($P=0.016$) and 138 days vs. 90 days ($P=0.036$), respectively.

Conclusion: Besides KRAS, assessing BRAF mutation should also be required to select patients eligible for Cetuximab. Further prospective evaluation in large samples should be performed to confirm these preliminary findings.

Key words: KRAS; BRAF; Mutation; Cetuximab; Colorectal cancer

INTRODUCTION

The mortality and morbidity of colorectal cancer (CRC) in China are increasing day by day, and CRC becomes the third-leading cause of cancer-related deaths in China. Although the standard combination chemotherapy regimens containing 5-fluorouracil, oxaliplatin or irinotecan had brought significant improvement for CRC patients, the 5-year survival rate of CRC was still low^[1]. Recently, Cetuximab, one monoclonal antibody targeting epidermal growth factor receptor (EGFR), has been proved to be effective in about 10%–20% CRC patients^[2,3]. Cetuximab plays its role through binding to EGFR and inhibiting the downstream RAS/RAF/MEK/ERK or PI3K/PTEN/AKT signal pathways, but no association was seen between EGFR expression and Cetuximab efficacy^[4,5].

KRAS and BRAF are two of molecules downstream

of EGFR and play an important role in EGFR signaling cascade. The activating mutations in exon 2 of KRAS can induce unlimited proliferation of tumor cells, thus isolating the pathway from the control of EGFR^[6,7]. Others have reported that KRAS mutations could become an independent prognostic factor in advanced CRC patients treated with Cetuximab, and patients with mutated KRAS could not benefit from Cetuximab^[8,9]. So, detection of KRAS mutations is strongly recommended by FDA before administration of Cetuximab. Nevertheless, not all patients with wild-type KRAS had a response to Cetuximab, maybe other molecules downstream of EGFR could affect the response to Cetuximab.

Phosphatase and tensin (PTEN) is one of downstream molecules of EGFR, and the loss of PTEN protein can stimulate the proliferation of cancer cells^[10]. Studies in western populations have demonstrated that positive PTEN expression could predict the response to Cetuximab^[11], which was consistent with the result performed in Chinese CRC patients^[12]. As another downstream molecule of EGFR, BRAF also plays an

Received: 2011-03-21; Accepted: 2011-06-17

*Corresponding author.

E-mail: lin100@medmail.com.cn

important role in CRC. BRAF mutation in western CRC patients was associated with poor prognosis, and patients with BRAF mutation could not respond to Cetuximab or had shorter progression-free survival (PFS) and shorter overall survival (OS)^[13-16]. However, according to recent analysis from prospective data in CRYSTAL trial, BRAF status could not predict the benefit of addition of Cetuximab, and only as a predictive marker (paper presented in 2010 ASCO GI, not published). These results indicated that BRAF mutation as a predictive marker is controversial and more important as a prognostic marker. Up to now, little is known about the correlation between BRAF mutation and the activity of Cetuximab in Chinese CRC patients. So, this study was conducted to evaluate simultaneously the associations between KRAS, BRAF mutations and the response to Cetuximab in Chinese metastatic CRC (mCRC) patients.

MATERIALS AND METHODS

Patients and Mutation Analysis

A total of 273 histologically confirmed CRC patients with primary tumor tissues treated in Beijing Cancer Hospital from August 2005 to July 2009 were evaluated for KRAS and BRAF mutations in this study. Genomic DNA of formalin-fixed, paraffin-embedded (FFPE) sections with $\geq 50\%$ tumor cells (if the content of tumor cells in sections was lower than 50%, the sections would be microdissected) was extracted using E.Z.N.A. FFPE DNA Kit (Lot. D3399-01, OMEGA, USA) according to the manufacturer's instructions. All genomic DNAs were stored at -20°C until further research. A DNA fragment including codons 12 and 13 in exon 2 of KRAS gene was amplified by PCR using primers (KRAS-F: 5'-GGTACTGGTGGAGTATTTGATAG-3', KRAS-R: 5'-TGGTCCTGCACCAGTAATATG-3') with a product size of 248 bp. Another DNA fragment including exon 15 of BRAF gene was amplified by PCR using primers (BRAF-F: 5'-CTCTTCATAATGCTTGCTCTGATAGG-3', BRAF-R: 5'-GTGGAAAAATAGCCTCAATTCTTACC-3') with a product size of 211 bp. Each PCR reaction consisted of $10\times$ LA PCR buffer II 2 μl , 10 mmol/L dNTPs 2 μl , LA Taq 0.2 μl (DRR200A, TAKARA), genomic DNA 2 μl , 10 $\mu\text{mol/L}$ forward primer 0.5 μl , and 10 $\mu\text{mol/L}$ reverse primer 0.5 μl in a final volume of 20 μl . The cycling conditions were 94°C for 5 min, 45 cycles of 94°C for 30 s, 56°C for 30 s and 72°C for 20 s, final extension at 72°C for 10 min, and ended at 4°C . The PCR products were determined by 3% agarose gel electrophoresis and then sequenced using the same forward primer of each gene by Invitrogen 3730XL genetic analyzer. The sequencing results were analyzed with Chromas software under the condition of signal/noise $>98\%$.

Treatment of Patients

Among 273 patients, 59 patients with mCRC were treated with weekly Cetuximab (400 mg/ m^2 as an initial loading dose, and 250 mg/ m^2 subsequent dose) in

combination with chemotherapy (standard dose): 34 patients received Cetuximab plus oxaliplatin-based chemotherapy, 22 patients received Cetuximab plus irinotecan-based chemotherapy, and 3 patients received Cetuximab plus fluorouracil chemotherapy. Cetuximab was administered as first-line treatment in 27 patients, as second-line treatment in 14 patients, and as third-line or more treatment in 18 patients.

Response Evaluation and Survival of Patients

Tumor response was estimated every two months by computed tomography (CT) according to the Response Evaluation Criteria in Solid Tumors (RECIST)^[17]. Patients were categorized by complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The overall response rate was defined as (CR+PR)/Total, and the PFS was calculated from the initial treatment of Cetuximab to disease progression or death from any cause. The OS of patients was calculated from the initial treatment of Cetuximab to death from any cause.

Statistical Analysis

The relationships between KRAS, BRAF mutations and the response to Cetuximab were performed using Fisher's exact test. Kaplan-Meier curves and log-rank test were used to analyze the association between KRAS, BRAF mutations and PFS or OS, with its associated 95% confidence interval (95% CI). Statistical analysis was done using SPSS 13.0 (SPSS Inc, Chicago, Illinois, USA). $P < 0.05$ represents significant difference.

RESULTS

Patient Characteristics

Of all patients, the median age was 59 years (range 22–84 years) with 160 males and 113 females. Among 59 patients treated with Cetuximab, the median age was 57 years (range 24–81 years) with 38 males and 21 females. The primary locations of tumors were colon ($n=25$) and rectum ($n=33$), and one patients with primary locations both at colon and at rectum. More details are shown in Table 1.

KRAS and BRAF Mutational Profiling

Of the 273 CRC patients, 105 patients harbored KRAS mutations and 14 patients harbored BRAF mutations. The mutation types of KRAS in this study included G12D (43/105, 41.0%), G12V (20/105, 19.0%), G12S (9/105, 8.6%), G12C (8/105, 7.6%), G12A (7/105, 6.7%), G12R (1/105, 1.0%), and G13D (17/105, 16.2%). All BRAF mutations were V600E. Wild-type and representative mutant KRAS and BRAF profiles are shown in Figure 1. KRAS and BRAF mutations were mutually exclusive. Among 59 patients treated with Cetuximab, 11 patients harbored KRAS mutations (8 patients with codon 12 mutations, 3 patients with codon 13 mutations) and 5 patients harbored BRAF V600E mutation.

KRAS/BRAF Mutations and the Response or Survival